3-D Matrix Europe SAS
5
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
A Evaluation of the Utilisation, Effectiveness and Safety of Purastat® in the Management of Gastrointestinal Bleeding
Role: collaborator
IEIK13 For Neurosurgery
Role: lead
Post-market Clinical Study to Confirm Safety and Performance of PuraStat® for the Management of Bleeding in Vascular Surgery.
Role: lead
Purastat Prevention Delayed Bleeding Duodenum
Role: collaborator
Post-Market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Liver Surgery
Role: lead
All 5 trials loaded